Seelos’ IV-administered sugar therapy fails to improve ALS severity in midstage trial

Seelos had hoped to report a sweet victory for its amyotrophic lateral sclerosis treatment, but the IV-delivered sugar failed to distinguish itself in a phase 2/3 trial.

The New York biotech said Tuesday that SLS-005 didn't demonstrate a significant improvement in slowing disease severity compared to placebo, flunking the study’s primary endpoint. The treatment was also unable to spur a statistically significant improvement in patients’ physical function or mortality rates.